75 results on '"Trassard M"'
Search Results
2. Soft tissue sarcomas of the trunk wall (STS-TW): a study of 343 patients from the French Sarcoma Group (FSG) database
- Author
-
Salas, S., Bui, B., Stoeckle, E., Terrier, P., Ranchere-Vince, D., Collin, F., Leroux, A., Guillou, L., Michels, J.J., Trassard, M., Valo, I., Robin, Y.-M., Marques, B., Brouste, V., and Coindre, J.-M.
- Published
- 2009
- Full Text
- View/download PDF
3. Leiomyosarcoma of the great saphenous vein
- Author
-
El Khoury, M, Mesurolle, B, Trassard, M, Cherel, P, Talma, V, and Hagay, C
- Published
- 2006
4. Soft tissue sarcomas of the trunk wall (STS-TW): a study of 343 patients from the French Sarcoma Group (FSG) database
- Author
-
Salas, S., Bui, B., Stoeckle, E., Terrier, P., Ranchere-Vince, D., Collin, F., Leroux, A., Guillou, L., Michels, J. J., Trassard, M., Valo, I., Robin, Y.-M, Marques, B., Brouste, V., Coindre, J.-M, Salas, S., Bui, B., Stoeckle, E., Terrier, P., Ranchere-Vince, D., Collin, F., Leroux, A., Guillou, L., Michels, J. J., Trassard, M., Valo, I., Robin, Y.-M, Marques, B., Brouste, V., and Coindre, J.-M
- Abstract
Background: Soft tissue sarcomas of the trunk wall (STS-TW) are usually studied together with soft tissue sarcomas of other locations. We report a study on STS-TW forming part of the French Sarcoma Group database. Patients and methods: Three hundred and forty-three adults were included. We carried out univariate and multivariate analysis for overall survival (OS), metastasis-free survival (MFS) and local recurrence-free survival (LRFS). Results: Tumor locations were as follows: thoracic wall, 82.5%; abdominal wall, 12.3% and pelvic wall, 5.2%. Median tumor size was 6.0 cm. The most frequent tumor types were unclassified sarcoma (27.7%) and myogenic sarcoma (19.2%). A total of 44.6% of cases were grade 3. In all, 21.9% of patients had a previous medical history of radiotherapy (PHR). Median follow-up was 7.6 years. The 5-year OS, MFS and LRFS rates were 60.4%, 68.9% and 58.4%, respectively. Multivariate analysis retained PHR and grade for predicting LRFS and PHR, size and grade as prognostic factors of MFS. Factors influencing OS were age, size, PHR, depth, grade and surgical margins. The predictive factors of incomplete response were PHR, size and T3. Conclusions: Our results suggest similar classical prognostic factors as compared with sarcomas of other locations. However, a separate analysis of STS-TW revealed a significant poor prognosis subgroup of patients with PHR
- Published
- 2017
5. Uterine leiomyosarcoma metastatic to thyroid shown by 18 F-FDG PET/CT imaging
- Author
-
Gauthé, M., primary, Testart Dardel, N., additional, Nascimento, C., additional, Trassard, M., additional, Banal, A., additional, and Alberini, J.-L., additional
- Published
- 2017
- Full Text
- View/download PDF
6. Uterine leiomyosarcoma metastatic to thyroid shown by 18F-FDG PET/CT imaging
- Author
-
Gauthé, M., primary, Testart Dardel, N., additional, Nascimento, C., additional, Trassard, M., additional, Banal, A., additional, and Alberini, J.-L., additional
- Published
- 2017
- Full Text
- View/download PDF
7. Can c-myc amplification reliably discriminate postradiation from primary angiosarcoma of the breast?
- Author
-
Laé, M., primary, Lebel, A., additional, Hamel-Viard, F., additional, Asselain, B., additional, Trassard, M., additional, Sastre, X., additional, and Kirova, Y.M., additional
- Published
- 2015
- Full Text
- View/download PDF
8. Abstract PD07-04: A randomized phase II neoadjuvant trial evaluating anastrozole and fulvestrant efficiency for post-menopausal ER-positive, HER2-negative Breast Cancer patients: first results of the UNICANCER CARMINA 02 French trial
- Author
-
Lerebours, F, primary, Bourgier, C, additional, Alran, S, additional, Mouret-Reynier, M-A, additional, Venat, Bouvet L, additional, Kerbrat, P, additional, Salmon, R, additional, Mijonnet, S, additional, Becette, V, additional, Trassard, M, additional, Spyratos, F, additional, Lebas, N, additional, Martin, A-L, additional, Lemonnier, J, additional, and Mouret-Fourme, E, additional
- Published
- 2012
- Full Text
- View/download PDF
9. MDGI, MIG-6 et EIG121 sont des inhibiteurs de la voie EGFR et des biomarqueurs potentiels de thérapies ciblées anti-EGFR dans les carcinomes mammaires invasifs
- Author
-
Meseure, D., primary, Drak elsibai, K., additional, Trassard, M., additional, Vacher, S., additional, le Ray, C., additional, Guinebretière, J.-M., additional, Lidereau, R., additional, and Bièche, I., additional
- Published
- 2012
- Full Text
- View/download PDF
10. P1-05-03: Relationship between Polycomb Repressive Complex EZH2/CBX7, Large Non-Coding RNA ANRIL and Stem Cells Biomarkers in Triple Negative Breast Carcinomas: Important Role in Carcinogenesis through an Epigenetic Silencing Process and New Clues for Targeted Therapies.
- Author
-
Meseure, D, primary, Vacher, S, additional, Trassard, M, additional, Drak-Alsibai, K, additional, Le Scodan, R, additional, Le Ray, C, additional, Regnier, C, additional, Lidereau, R, additional, and Bieche, I, additional
- Published
- 2011
- Full Text
- View/download PDF
11. Rôles du complexe répresseur Polycomb EZH2/CBX7 et du long ARN non codant ANRIL dans l’induction des mécanismes de silencing épigénétique. Implications thérapeutiques potentielles dans les carcinomes mammaires de type triple négatif
- Author
-
Meseure, D., primary, Vacher, S., additional, Trassard, M., additional, Drak Alsibai, K., additional, Le Ray, C., additional, Régnier, C., additional, Lerebours, F., additional, Le Scodan, R., additional, Lidereau, R., additional, and Bièche, I., additional
- Published
- 2011
- Full Text
- View/download PDF
12. Outcome of 157 adult rhabdomyosarcoma (RMS) patients: A retrospective study from the French Group Sarcoma (GSF-GETO).
- Author
-
Bompas, E., primary, Campion, L., additional, Italiano, A., additional, Cesne, A. l., additional, Giaj Levra, M., additional, Chevreau, C., additional, Piperno-Neumann, S., additional, Isambert, N., additional, Thyss, A., additional, Rios, M., additional, Kurtz, J., additional, Delcambre, C., additional, Bay, J., additional, Duffaud, F., additional, Trassard, M., additional, Soulie, P., additional, and Blay, J., additional
- Published
- 2011
- Full Text
- View/download PDF
13. Effect of adjuvant chemotherapy on survival in FNCLCC grade 3 soft tissue sarcomas: A multivariate analysis of the French Sarcoma Group database
- Author
-
Italiano, A., primary, Delva, F., additional, Brouste, V., additional, Terrier, P., additional, Trassard, M., additional, Michels, J., additional, Collin, F., additional, Coindre, J., additional, Blay, J., additional, and Bui, B., additional
- Published
- 2009
- Full Text
- View/download PDF
14. Les facteurs pronostiques de survie globale chez des patients atteints de sarcomes des tissus mous : impact clinique des approches statistiques vérifiant la proportionnalité des risques
- Author
-
Delva, F., primary, Bellera, C., additional, Bui, B.N., additional, Italiano, A., additional, Coindre, J.-M., additional, Terrier, P., additional, Trassard, M., additional, Michels, J.-J., additional, Brouste, V., additional, and Mathoulin-Pélissier, S., additional
- Published
- 2009
- Full Text
- View/download PDF
15. Test de reproductibilité inter-observateurs de l’évaluation immunohistochimique du Ki67 dans les cancers du sein en situation adjuvante dans le cadre de l’essai clinique RAPP01
- Author
-
Trassard, M., primary, Guinebretière, J.M., additional, Fourme, E., additional, Picquenot, J.M., additional, Treilleux, I., additional, Rigaud, C., additional, Sastre-Garau, X., additional, Digneton, H.G., additional, De Ybarlucea, L.R., additional, Verrièle, V., additional, Spyratos, F., additional, and Brain, E., additional
- Published
- 2006
- Full Text
- View/download PDF
16. Cytology vs molecular analysis for the detection of head and neck squamous cell carcinoma in oesopharyngeal brush samples: a prospective study in 56 patients
- Author
-
Temam, S, primary, Trassard, M, additional, Leroux, G, additional, Bosq, J, additional, Luboinski, B, additional, Lenoir, G, additional, Bénard, J, additional, and Janot, F, additional
- Published
- 2003
- Full Text
- View/download PDF
17. Soft tissue sarcomas of the trunk wall (STS-TW): a study of 343 patients from the French Sarcoma Group (FSG) database
- Author
-
Salas, S., Bui, B., Stoeckle, E., Terrier, P., Ranchere-Vince, D., Collin, F., Leroux, A., Guillou, L., Michels, J. J., Trassard, M., Valo, I., Robin, Y.-M, Marques, B., Brouste, V., Coindre, J.-M, Salas, S., Bui, B., Stoeckle, E., Terrier, P., Ranchere-Vince, D., Collin, F., Leroux, A., Guillou, L., Michels, J. J., Trassard, M., Valo, I., Robin, Y.-M, Marques, B., Brouste, V., and Coindre, J.-M
- Abstract
Background: Soft tissue sarcomas of the trunk wall (STS-TW) are usually studied together with soft tissue sarcomas of other locations. We report a study on STS-TW forming part of the French Sarcoma Group database. Patients and methods: Three hundred and forty-three adults were included. We carried out univariate and multivariate analysis for overall survival (OS), metastasis-free survival (MFS) and local recurrence-free survival (LRFS). Results: Tumor locations were as follows: thoracic wall, 82.5%; abdominal wall, 12.3% and pelvic wall, 5.2%. Median tumor size was 6.0 cm. The most frequent tumor types were unclassified sarcoma (27.7%) and myogenic sarcoma (19.2%). A total of 44.6% of cases were grade 3. In all, 21.9% of patients had a previous medical history of radiotherapy (PHR). Median follow-up was 7.6 years. The 5-year OS, MFS and LRFS rates were 60.4%, 68.9% and 58.4%, respectively. Multivariate analysis retained PHR and grade for predicting LRFS and PHR, size and grade as prognostic factors of MFS. Factors influencing OS were age, size, PHR, depth, grade and surgical margins. The predictive factors of incomplete response were PHR, size and T3. Conclusions: Our results suggest similar classical prognostic factors as compared with sarcomas of other locations. However, a separate analysis of STS-TW revealed a significant poor prognosis subgroup of patients with PHR
18. Rôles du complexe répresseur Polycomb EZH2/CBX7 et du long ARN non codant ANRIL dans l’induction des mécanismes de silencingépigénétique. Implications thérapeutiques potentielles dans les carcinomes mammaires de type triple négatif
- Author
-
Meseure, D., Vacher, S., Trassard, M., Drak Alsibai, K., Le Ray, C., Régnier, C., Lerebours, F., Le Scodan, R., Lidereau, R., and Bièche, I.
- Published
- 2011
- Full Text
- View/download PDF
19. A randomized phase II neoadjuvant trial evaluating anastrozole and fulvestrant efficiency for post-menopausal ER-positive, HER2-negative Breast Cancer patients: first results of the UNICANCER CARMINA 02 French trial.
- Author
-
Lerebours, F., Bourgier, C., Alran, S., Mouret-Reynier, M.-A., Venat, Bouvet L., Kerbrat, P., Salmon, R., Mijonnet, S., Becette, V., Trassard, M., Spyratos, F., Lebas, N., Martin, A.-L., Lemonnier, J., and Mouret-Fourme, E.
- Subjects
- *
HORMONE therapy , *BREAST cancer surgery , *ESTROGEN receptors , *HER2 gene , *ANASTROZOLE - Abstract
Purpose: Neoadjuvant hormone therapy (HT) promotes breast-conserving surgery (BCS) and minimizes treatment-related toxicities for oestrogen receptor (ER)-positive HER2 negative breast cancer (BC). We aimed to evaluate the response rates to an AI (anastrozole) or an antioestrogen (fulvestrant) and to identify specific biomarkers of sensitivity to both treatments. Patients and Methods: A phase II multicentre, open-label trial was conducted to evaluate the efficacy of anastrozole and fulvestrant. 116 postmenopausal patients (pts) with ER positive, HER2 negative, operable BC were recruited in 6 centers and randomly assigned to receive either neoadjuvant anastrozole (arm A; 1mg/day) or fulvestrant (arm B; 500mg, with a loading dose during first month then q4w) for 4 months (mo). Pts with a good clinical response estimated by the clinician at 4 mo were allowed to pursue treatment for 2 more mo (i.e. up to 6 mo). The primary endpoint was to evaluate the best clinical response (by palpation) by RECIST criteria at 6 mo (or 4 mo). US and MR imaging were performed at baseline, after 1 mo treatment, and before surgery. Pathological response was evaluated using Sataloff classification. Follow-up is planned for 5 yrs. Results: Between Oct 2007 and Apr 2011, 59 pts were randomized to arm A and 57 to arm B. Main baseline characteristics were well-balanced between the 2 arms: Median age was 68 yrs- old (53-91) in arm A and 74 yrs-old (51-88) in arm B. Histological grades were EE I-II in 53 pts (89 %) and 49 pts (86%) and median clinical size before treatment was 41.5 mm and 42.3 mm in arm A and B respectively. Neither SAE nor grade 3/4 toxicity was reported. The most common treatment-related AEs were grade1/2 hot flushes (27% and 12% of pts in arm A and B respectively), and musculoskeletal symptoms (20% and 21%). 35 pts in arm A and 29 pts in arm B continued assigned treatment up to 6 mo depending on the clinical response evaluated at 4 mo. Also, the clinical response rate was estimated at 4 mo orat 6 mo. 1 death post-surgery was reported in arm B with no proven relationship with treatment. Overall clinical response rates (CR + PR) at 4 or 6 mo were 62% (CI 95% [49-75]) in arm A and 46% (CI 95% [32-59]) in arm B. Clinical response rate amelioration at 6 mo was observed among 15% of pts in each arm. BCS was performed in 59% of pts in arm A and 49% in arm B. (1 pt from arm B refused surgery). Pathological response according to Sataloff classification: TA and TB tumor responses were observed in 17/59 pts (29%) in arm A vs 12/57 (21%) in arm B respectively. Conclusions: Both anastrozole and fulvestrant show excellent efficacy and tolerability as neoadjuvant therapy in post-menopausal pts with endocrine-dependent, HER2-negative BC. Objective response rates and improvement in surgical outcome seem to be more frequent with anastrozole. However disease stabilization and tolerability are in favour of fulvestrant. Our data suggest that neo-adjuvant HT improves surgical options for HR+ post-menopausal women. Correlation between clinical & pathological responses and outcome as well as the identification of markers of sensitivity to both treatments will be also studied. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
20. The Identification of Large Rearrangements Involving Intron 2 of the CDH1 Gene in BRCA1/2 Negative and Breast Cancer Susceptibility.
- Author
-
Ben Aissa-Haj J, Pinheiro H, Cornelis F, Sebai M, Meseure D, Briaux A, Berteaux P, Lefol C, Des Guetz G, Trassard M, Stevens D, Vialard F, Bieche I, Noguès C, Tang R, Oliveira C, Stoppat-Lyonnet D, Lidereau R, and Rouleau E
- Subjects
- Humans, Female, Introns genetics, DNA Copy Number Variations, Genetic Predisposition to Disease, Pedigree, BRCA1 Protein genetics, Antigens, CD genetics, Cadherins genetics, Breast Neoplasms genetics, Breast Neoplasms pathology
- Abstract
E-cadherin, a CDH1 gene product, is a calcium-dependent cell-cell adhesion molecule playing a critical role in the establishment of epithelial architecture, maintenance of cell polarity, and differentiation. Germline pathogenic variants in the CDH1 gene are associated with hereditary diffuse gastric cancer (HDGC), and large rearrangements in the CDH1 gene are now being reported as well. Because CDH1 pathogenic variants could be associated with breast cancer (BC) susceptibility, CDH1 rearrangements could also impact it. The aim of our study is to identify rearrangements in the CDH1 gene in 148 BC cases with no BRCA1 and BRCA2 pathogenic variants. To do so, a zoom-in CGH array, covering the exonic, intronic, and flanking regions of the CDH1 gene, was used to screen our cohort. Intron 2 of the CDH1 gene was specifically targeted because it is largely reported to include several regulatory regions. As results, we detected one large rearrangement causing a premature stop in exon 3 of the CDH1 gene in a proband with a bilateral lobular breast carcinoma and a gastric carcinoma (GC). Two large rearrangements in the intron 2, a deletion and a duplication, were also reported only with BC cases without any familial history of GC. No germline rearrangements in the CDH1 coding region were detected in those families without GC and with a broad range of BC susceptibility. This study confirms the diversity of large rearrangements in the CDH1 gene. The rearrangements identified in intron 2 highlight the putative role of this intron in CDH1 regulation and alternative transcripts. Recurrent duplication copy number variations (CNV) are found in this region, and the deletion encompasses an alternative CDH1 transcript. Screening for large rearrangements in the CDH1 gene could be important for genetic testing of BC.
- Published
- 2022
- Full Text
- View/download PDF
21. Lower Rate of CTNNB1 Mutations and Higher Rate of APC Mutations in Desmoid Fibromatosis of the Breast: A Series of 134 Tumors.
- Author
-
Norkowski E, Masliah-Planchon J, Le Guellec S, Trassard M, Courrèges JB, Charron-Barra C, Terrier P, Bonvalot S, Coindre JM, and Laé M
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Breast Neoplasms pathology, Breast Neoplasms therapy, Breast Neoplasms, Male pathology, Breast Neoplasms, Male therapy, Female, Fibromatosis, Aggressive pathology, Fibromatosis, Aggressive therapy, France, Genetic Predisposition to Disease, Humans, Male, Middle Aged, Mutation Rate, Phenotype, Prognosis, Young Adult, Adenomatous Polyposis Coli Protein genetics, Biomarkers, Tumor genetics, Breast Neoplasms genetics, Breast Neoplasms, Male genetics, Fibromatosis, Aggressive genetics, Mutation, beta Catenin genetics
- Abstract
Desmoid fibromatosis (DF) is a rare, locally aggressive, nonmetastasizing fibroblastic/myofibroblastic tumor with a tendency to recur and an unpredictable clinical course. A "wait-and-see" policy is the new standard of care. DF are characterized by activating alterations of the wnt/β-catenin pathway: CTNNB1 or adenomatous polyposis coli gene (APC) mutations (these mutations being mutually exclusive). Desmoid-type fibromatosis of the breast (DFB) is rare with an incidence of 0.2% of breast tumors. The diagnosis of DFB is difficult, as it must be distinguished from metaplastic carcinoma and other spindle cell lesions. Sequencing of 128 DFB identified a lower rate of CTNNB1 mutations using Sanger (65.6%) or Sanger+next-generation sequencing (77.7%) and a higher rate of APC mutations (11.8%) than in all-site DF. By excluding patients with familial adenomatous polyposis (n=2), the rate of APC mutations in DFB was high (10.7%). The distribution of CTNNB1 mutations in DFB was different from all-site DF, with a higher rate of T41A (68.9%), a lower rate of S45F (5.7%), and a similar rate of S45T (12.6%). By combining the 2 molecular techniques in a 2-step manner (Sanger, then next-generation sequencing), we increased the detection rate of CTNNB1 mutations and lowered the rate of wild-type tumors from 34.4% to 9.8%, therefore improving the diagnosis of DFB. The identification of the exon 3 CTNNB1 mutation in breast spindle cell lesions is a highly specific tool for the diagnosis of DFB, in addition to extensive immunohistochemical analysis. Our study also underlines the importance of APC in DFB tumorigenesis. These findings have significant implications for patient care and management.
- Published
- 2020
- Full Text
- View/download PDF
22. Biopathological Significance of TLR9 Expression in Cancer Cells and Tumor Microenvironment Across Invasive Breast Carcinomas Subtypes.
- Author
-
Meseure D, Vacher S, Drak Alsibai K, Trassard M, Nicolas A, Leclere R, Lerebours F, Guinebretiere JM, Marangoni E, Lidereau R, and Bieche I
- Abstract
Toll-like receptors (TLRs) are pattern recognition receptors mainly expressed by cells of the immune system but also by epithelial tumor cells. Little is known about expression patterns of TLR genes in breast tumors, and their clinical significance is unclear. The aim of our study was to investigate expression of TLRs pathway components in pre-invasive breast lesions and invasive breast carcinomas (IBCs). We used RT-PCR assays to quantify mRNA levels of the 10 TLR genes and genes involved in TLR pathways in 350 breast tumors from patients with known clinical/pathological status and long-term outcome. Sets of 158 breast samples were also analyzed by immunochemistry including; 40 early noninvasive breast lesions, 38 IBCs and 80 triple negative carcinomas subtype (TNCs). We identified TLR9 as the major TLR gene family member upregulated in breast tumors and more particularly in TNCs. Immunohistochemical studies demonstrated that TLR9 protein was expressed in tumor epithelial and stromal cells of the TLR9 mRNA-overexpressing tumors. TLR9 overexpression appears very early during breast carcinogenesis. High TLR9 levels were associated with favorable outcome in the TNC sub-group. TLR9 overexpression was associated with alterations of down-stream components of the TLR9 signaling pathway, epithelio-mesenchymal transition (EMT) induction and EGFR pathway deregulation. TNCs with TLR9 overexpression were significantly correlated with development of a fibrous and inflammatory microenvironment with variable status of nuclear phosphoSTAT3. Our results suggest that TLR9 could play a role in TNC carcinogenesis and could be useful as predictive biomarker and therapeutic target., Competing Interests: Compliance With Ethical Standards Grant Support This work was supported by the Conseil régional d’Ile-de-France, the Cancéropôle Ile-de-France, the Comité départemental des Hauts-de-Seine de la Ligue Nationale Contre le Cancer and the Association pour la recherche en cancérologie de Saint-Cloud (ARCS), and by grant INCa-DGOS-4654. Conflict of Interest The authors declare no conflict of interest.
- Published
- 2016
- Full Text
- View/download PDF
23. [A hybrid lesion: Low-grade fibromyxoid sarcoma (LGFMS) and sclerosing epithelioid fibrosarcoma (SEF)].
- Author
-
Kesrouani C, Zemoura L, Trassard M, and Laé M
- Subjects
- Adult, Axilla, Calmodulin-Binding Proteins analysis, Combined Modality Therapy, Female, Fibrosarcoma chemistry, Fibrosarcoma diagnosis, Fibrosarcoma therapy, Humans, Mucin-4 analysis, Neoplasm Proteins analysis, Neoplasms, Multiple Primary chemistry, Neoplasms, Multiple Primary diagnosis, Neoplasms, Multiple Primary therapy, RNA-Binding Protein EWS, RNA-Binding Protein FUS analysis, RNA-Binding Proteins analysis, Radiotherapy, Adjuvant, Soft Tissue Neoplasms chemistry, Soft Tissue Neoplasms diagnosis, Soft Tissue Neoplasms therapy, Fibrosarcoma pathology, Neoplasms, Multiple Primary pathology, Soft Tissue Neoplasms pathology
- Abstract
We report the case of a 34-year-old woman presenting a 10cm axillary mass diagnosed as hybrid tumor low-grade fibromyxoid sarcoma/sclerosing epithelioid fibrosarcoma. Microbiopsy for morphological and immunohistochemical analyses was associated with molecular analysis (FISH and PCR) to confirm the diagnosis., (Copyright © 2016 Elsevier Masson SAS. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
24. Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial (UCBG 0609).
- Author
-
Lerebours F, Rivera S, Mouret-Reynier MA, Alran S, Venat-Bouvet L, Kerbrat P, Salmon R, Becette V, Bourgier C, Cherel P, Boussion V, Balleyguier C, Thibault F, Lavau-Denes S, Nabholz JM, Sigal B, Trassard M, Mathieu MC, Martin AL, Lemonnier J, and Mouret-Fourme E
- Subjects
- Aged, Aged, 80 and over, Anastrozole, Breast Neoplasms metabolism, Breast Neoplasms pathology, Carcinoma, Ductal, Breast metabolism, Carcinoma, Ductal, Breast pathology, Carcinoma, Lobular metabolism, Carcinoma, Lobular pathology, Estradiol administration & dosage, Estradiol analogs & derivatives, Female, Follow-Up Studies, France, Fulvestrant, Humans, Middle Aged, Neoplasm Staging, Nitriles administration & dosage, Postmenopause, Prognosis, Survival Rate, Triazoles administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms drug therapy, Carcinoma, Ductal, Breast drug therapy, Carcinoma, Lobular drug therapy, Neoadjuvant Therapy, Receptor, ErbB-2 metabolism
- Abstract
Background: Treatment strategies for locally advanced breast cancer in elderly patients too frail to receive neoadjuvant chemotherapy and the introduction of new classes of drugs in the early 2000s have led to the consideration of endocrine therapy as a neoadjuvant treatment for younger hormone receptor (HR)-positive, postmenopausal patients not eligible for primary breast-conserving surgery (BCS)., Methods: This was a multicenter, phase 2, randomized trial designed to evaluate as its primary objective the clinical response rate after up to 6 months of neoadjuvant endocrine therapy (NET) alone in HR-positive/human epidermal growth factor receptor 2 (HER2)-negative patients with 1 mg of anastrozole (arm A) or 500 mg of fulvestrant (arm B). Secondary objectives included the BCS rate, tumor response assessment (breast ultrasound and magnetic resonance imaging), pathological response (Sataloff classification), safety profile, relapse-free survival (RFS), and predictive markers of responses and outcomes., Results: From October 2007 to April 2011, 116 women (mean age, 71.6 years) with operable infiltrating breast adenocarcinoma (T2-T4, N0-N3, M0) were randomized to receive anastrozole or fulvestrant. The clinical response rates at 6 months were 52.6% (95% confidence interval [CI], 41%-64%) in arm A and 36.8% (95% CI, 25%-49%) in arm B. BCS was performed for 57.6% of arm A patients and 50% of arm B patients. The RFS rates at 3 years were 94.9% in arm A and 91.2% in arm B. The Preoperative Endocrine Prognostic Index status was significantly predictive of RFS. Both treatments were well tolerated., Conclusions: Both drugs are effective and well tolerated as NET in postmenopausal women with HR-positive/HER2-negative breast cancer. NET could be considered a treatment option in this subpopulation. Cancer 2016;122:3032-3040. © 2016 American Cancer Society., (© 2016 American Cancer Society.)
- Published
- 2016
- Full Text
- View/download PDF
25. [Pre-analytical stage for biomarker assessment in breast cancer: 2014 update of the GEFPICS' guidelines in France].
- Author
-
MacGrogan G, Mathieu MC, Poulet B, Penault-Llorca F, Vincent-Salomon A, Roger P, Treilleux I, Valent A, Antoine M, Becette V, Bor C, Brabencova E, Charafe-Jauffret E, Chenard MP, Dauplat MM, Delrée P, Devouassoux M, Fiche M, Fondrevelle ME, Fridman V, Garbar C, Genin P, Ghnassia JP, Haudebourg J, Laberge-Le Couteulx S, Loussouarn D, Maran-Gonzalez A, Marcy M, Michenet P, Sagan C, Trassard M, Verriele V, Arnould L, and Lacroix-Triki M
- Subjects
- Breast Neoplasms pathology, Female, Fixatives, France, Histological Techniques, Humans, Prognosis, Quality Control, Receptors, Estrogen analysis, Receptors, Progesterone analysis, Specimen Handling methods, Biomarkers, Tumor analysis, Breast Neoplasms chemistry, Immunohistochemistry methods, In Situ Hybridization methods, Receptor, ErbB-2 analysis, Receptors, Steroid analysis
- Abstract
Biomarker assessment of breast cancer tumor samples is part of the routine workflow of pathology laboratories. International guidelines have recently been updated, with special regards to the pre-analytical steps that are critical for the quality of immunohistochemical and in situ hybridization procedures, whatever the biomarker analyzed. Fixation and specimen handling protocols must be standardized, validated and carefully tracked. Cooperation and training of the personnel involved in the specimen workflow (e.g. radiologists, surgeons, nurses, technicians and pathologists) are of paramount importance. The GEFPICS' update of the recommendations herein details and comments the different steps of the pre-analytical process. Application of these guidelines and participation to quality insurance programs are mandatory to ensure the correct evaluation of oncotheranostic biomarkers., (Copyright © 2014 Elsevier Masson SAS. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
26. [2014 update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France].
- Author
-
Penault-Llorca F, Vincent-Salomon A, MacGrogan G, Roger P, Treilleux I, Valent A, Mathieu MC, Antoine M, Becette V, Bor C, Brabencova E, Charafe-Jauffret E, Chenard MP, Dauplat MM, Delrée P, Devouassoux M, Fiche M, Fondrevelle ME, Fridman V, Garbar C, Genin P, Ghnassia JP, Haudebourg J, Laberge-Le Couteulx S, Loussouarn D, Maran-Gonzalez A, Marcy M, Michenet P, Poulet B, Sagan C, Trassard M, Verriele V, Arnould L, and Lacroix-Triki M
- Subjects
- Breast Neoplasms drug therapy, False Negative Reactions, Female, France, Humans, Immunohistochemistry methods, In Situ Hybridization, In Situ Hybridization, Fluorescence, Neoplasm Metastasis pathology, Neoplasm Recurrence, Local, Prognosis, Biomarkers, Tumor analysis, Breast Neoplasms chemistry, Breast Neoplasms pathology, Receptor, ErbB-2 analysis
- Abstract
International guidelines on HER2 determination in breast cancer have just been updated by the American Society of Clinical Oncology (ASCO) and College of American Pathologists (CAP), on the basis of more than ten-year practice, results of clinical trials and concordance studies. The GEFPICS group, composed of expert pathologists in breast cancer, herein presents these recommendations, adapted to the French routine practice. These guidelines highlight the possible diagnosis difficulties with regards to HER2 status determination, such as intra-tumor heterogeneity, special histological subtypes and biomarker re-evaluation during metastatic relapse. Pre-analytical issues and updated scoring criteria (especially for equivocal cases) are detailed, in order to decrease the occurrence of false negative cases. In the era of personalized medicine, pathologists are more than ever involved in the quality of oncotheranostic biomarker evaluation., (Copyright © 2014 Elsevier Masson SAS. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
27. PIK3R1 underexpression is an independent prognostic marker in breast cancer.
- Author
-
Cizkova M, Vacher S, Meseure D, Trassard M, Susini A, Mlcuchova D, Callens C, Rouleau E, Spyratos F, Lidereau R, and Bièche I
- Subjects
- Adult, Aged, Aged, 80 and over, Breast Neoplasms metabolism, Breast Neoplasms mortality, Class I Phosphatidylinositol 3-Kinases, Class Ia Phosphatidylinositol 3-Kinase, Female, Humans, Middle Aged, Mutation, Phosphatidylinositol 3-Kinases metabolism, Prognosis, Proto-Oncogene Proteins c-akt genetics, Proto-Oncogene Proteins c-akt metabolism, RNA, Messenger genetics, RNA, Messenger metabolism, Signal Transduction, Breast Neoplasms genetics, Gene Expression Regulation, Neoplastic, Phosphatidylinositol 3-Kinases genetics
- Abstract
Background: The present study focused on the prognostic roles of PIK3CA and PIK3R1 genes and additional PI3K pathway-associated genes in breast cancer., Methods: The mutational and mRNA expression status of PIK3CA, PIK3R1 and AKT1, and expression status of other genes involved in the PI3K pathway (EGFR, PDK1, PTEN, AKT2, AKT3, GOLPH3, WEE1, P70S6K) were assessed in a series of 458 breast cancer samples., Results: PIK3CA mutations were identified in 151 samples (33.0%) in exons 1, 2, 9 and 20. PIK3R1 mutations were found in 10 samples (2.2%) and underexpression in 283 samples (61.8%). AKT1 mutations were found in 15 samples (3.3%) and overexpression in 116 samples (25.3%). PIK3R1 underexpression tended to mutual exclusivity with PIK3CA mutations (p = 0.00097). PIK3CA mutations were associated with better metastasis-free survival and PIK3R1 underexpression was associated with poorer metastasis-free survival (p = 0.014 and p = 0.00028, respectively). By combining PIK3CA mutation and PIK3R1 expression status, four prognostic groups were identified with significantly different metastasis-free survival (p = 0.00046). On Cox multivariate regression analysis, the prognostic significance of PIK3R1 underexpression was confirmed in the total population (p = 0.0013) and in breast cancer subgroups., Conclusions: PIK3CA mutations and PIK3R1 underexpression show opposite effects on patient outcome and could become useful prognostic and predictive factors in breast cancer.
- Published
- 2013
- Full Text
- View/download PDF
28. Genetic profiling identifies two classes of soft-tissue leiomyosarcomas with distinct clinical characteristics.
- Author
-
Italiano A, Lagarde P, Brulard C, Terrier P, Laë M, Marques B, Ranchere-Vince D, Michels JJ, Trassard M, Cioffi A, Piperno-Neumann S, Chevreau C, Blay JY, Delcambre C, Isambert N, Penel N, Bay JO, Bonvalot S, Le Cesne A, Coindre JM, and Chibon F
- Subjects
- Adult, Aged, Aged, 80 and over, Cohort Studies, Combined Modality Therapy, Comparative Genomic Hybridization, Female, Follow-Up Studies, Humans, Leiomyosarcoma genetics, Leiomyosarcoma pathology, Male, Middle Aged, Neoplasm Grading, Neoplasm Recurrence, Local diagnosis, Oligonucleotide Array Sequence Analysis, Prognosis, Soft Tissue Neoplasms genetics, Soft Tissue Neoplasms pathology, Survival Rate, Young Adult, Biomarkers, Tumor genetics, Gene Expression Profiling, Leiomyosarcoma classification, Neoplasm Recurrence, Local genetics, Soft Tissue Neoplasms classification
- Abstract
Purpose: Data about the prognostic factors of soft-tissue leiomyosarcomas and their correlation with molecular profile are limited., Experimental Design: From 1990 to 2010, 586 adult patients with a primary soft-tissue leiomyosarcoma were included in the French Sarcoma Group (GSF) database after surgery of the primary tumor. Multivariate analyses were conducted by Cox regression model in a backward stepwise procedure. Genetic profiling was conducted for 73 cases., Results: Median age was 59 years (range, 21-98 years). The median follow-up of patients alive was 46 months. The 5-year metastasis-free survival (MFS) rate was 51% (95% location and grade > I were independent adverse prognostic factors for MFS). The 5-year overall survival (OS) rate was 63% [95% confidence interval (CI), 59-67]. On multivariate analysis, age ≥ 60 years old, tumor size > 5 cm, deep location, and grade > I were independent adverse prognostic factors for OS. Molecular profiling identified specific clusters with activation of different biologic pathways: retroperitoneal leiomyosarcomas are characterized by overexpression of genes involved in muscle differentiation and nonretroperitoneal leiomyosarcomas characterized by overexpression of genes mainly involved in extracellular matrix, wounding, and adhesion pathways. The CINSARC signature but not comparative genomic hybridization (CGH) profiling was predictive of outcome., Conclusion: Soft-tissue leiomyosarcomas represent a heterogeneous group of tumors with at least two categories, retroperitoneal and extremities leiomyosarcomas, having specific clinical outcome and molecular features. Future clinical trials should consider this heterogeneity for a better stratification of patients., (©2013 AACR.)
- Published
- 2013
- Full Text
- View/download PDF
29. Localised angiosarcomas: the identification of prognostic factors and analysis of treatment impact. A retrospective analysis from the French Sarcoma Group (GSF/GETO).
- Author
-
Lindet C, Neuville A, Penel N, Lae M, Michels JJ, Trassard M, Terrier P, Birtwisle-Peyrottes I, Valo I, Collin F, Chateau MC, Robin YM, and Coindre JM
- Subjects
- Adult, Age Factors, Aged, Aged, 80 and over, Female, France, Hemangiosarcoma drug therapy, Humans, Kaplan-Meier Estimate, Lymphedema pathology, Male, Middle Aged, Neoadjuvant Therapy, Prognosis, Retrospective Studies, Survival Analysis, Treatment Outcome, Young Adult, Hemangiosarcoma pathology, Hemangiosarcoma therapy
- Abstract
Background: Angiosarcomas represent less than 2% of all adult soft tissue sarcomas. Prognostic factors and the role of (neo-) adjuvant treatments in the management of localised angiosarcomas require further investigation., Methods: We have conducted a retrospective multicenter study (June 1980 to October 2009) of 107 patients with localised angiosarcomas. All of the cases were centrally reviewed by a certified pathologist. Univariate and multivariate analyses were conducted to identify independent poor prognostic factors (PF). Overall survival (OS) and Local Recurrence-Free Survival (LRFS) were estimated using the Kaplan-Meier method. The effect of treatments was explored using the Cox model after adjusting for the PF., Results: The median age was 71 years. 22.4% and 62.6% developed an angiosarcoma in pre-existing lymphoedema and within irradiated tissue respectively. The median OS, LRFS and Disease Recurrence-Free Survival (DRFS) were 38.8, 27 and 36.1 months, respectively. In multivariate analysis, the following parameters influenced the OS: lymphoedema (Hazard ratio (HR)=2.0) and size >5cm (HR=1.5). After adjustment to these PF, R0 margins was the only treatment parameter that improving the OS (HR=0.2). In the multivariate analysis, the LRFS was influenced by an age >70 (HR=1.8) and pre-existing lymphoedema (HR=2.0). After adjustment for these PF, R0 margins (HR=0.5) and adjuvant radiotherapy (HR=0.3) improved the LRFS., Conclusions: Our results suggest the following points: (i) pre-existing lymphoedema, tumour size and age >70 are probably the major prognostic factors in patients with localised angiosarcomas; (ii) the achievement of R0 margins is probably of major importance for improving the patient outcome and (iii) adjuvant radiotherapy probably decreased the risk of local recurrence., (Copyright © 2012 Elsevier Ltd. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
30. Profiling of EGFR mRNA and protein expression in 471 breast cancers compared with 10 normal tissues: a candidate biomarker to predict EGFR inhibitor effectiveness.
- Author
-
Meseure D, Vacher S, Drak Alsibai K, Trassard M, Susini A, Le Ray C, Lerebours F, Le Scodan R, Spyratos F, Marc Guinebretiere J, Lidereau R, and Bieche I
- Subjects
- Biomarkers, Tumor genetics, Breast Neoplasms pathology, Case-Control Studies, ErbB Receptors antagonists & inhibitors, ErbB Receptors genetics, Female, Humans, Mutation, Biomarkers, Tumor metabolism, Breast Neoplasms genetics, ErbB Receptors metabolism, RNA, Messenger genetics
- Published
- 2012
- Full Text
- View/download PDF
31. [Update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France].
- Author
-
Penault-Llorca F, Vincent-Salomon A, Bellocq JP, Matthieu MC, Grogan GM, Treilleux I, Ettore F, Laberge-Le Couteulx S, Sigal B, Couturier J, Lacroix-Triki M, Antoine M, Balaton A, Baranzelli MC, Becette V, Blanc-Fournier C, Bibeau F, Brabencova E, Croce S, Fridman V, Génin P, Ghnassia JP, Jacquemier J, Poulet B, Roger P, Sagan C, Tas P, Trassard M, Verriele V, and Arnould L
- Subjects
- France, Humans, Immunohistochemistry standards, In Situ Hybridization standards, Quality Control, Records, Breast Neoplasms chemistry, Breast Neoplasms pathology, Receptor, ErbB-2 analysis
- Abstract
In Europe, patients who may benefit from an HER2 targeted drug are currently selected by immunohistochemistry (IHC). In situ hybridization (ISH) techniques should be used for complementary assessment of ambiguous 2+ IHC cases and for the calibration of the IHC technique. Eligibility to an HER2 target treatment is defined by an HER2 positive status being IHC test 3+ or 2+ amplified. Reliable detection of HER2 status is essential to the appropriate usage of HER2 targeted drugs because its specificity is limited to tumors overexpressing HER2. It is essential that the IHC evaluation of the HER2 status of a mammary carcinoma is optimized and reliable. This GEFPICS' guidelines look over the different steps of the IHC technique, the controls and, the rules for interpretation. Once acquired, this knowledge must be perpetuated by the observation of rules of good technical practice (internal and external controls, quality assurance programs)., (Copyright © 2010 Elsevier Masson SAS. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
32. Fusion of EWSR1 with the DUX4 facioscapulohumeral muscular dystrophy region resulting from t(4;22)(q35;q12) in a case of embryonal rhabdomyosarcoma.
- Author
-
Sirvent N, Trassard M, Ebran N, Attias R, and Pedeutour F
- Subjects
- Adult, Chromosomes, Human, Pair 22, Chromosomes, Human, Pair 4, Cytogenetic Analysis, Female, Humans, Immunohistochemistry, In Situ Hybridization, Fluorescence, Microfilament Proteins, Microscopy, Electron, Nuclear Proteins, RNA-Binding Protein EWS, Rhabdomyosarcoma, Embryonal pathology, Translocation, Genetic, Young Adult, Calmodulin-Binding Proteins genetics, Homeodomain Proteins genetics, Muscular Dystrophy, Facioscapulohumeral genetics, Oncogene Proteins, Fusion genetics, RNA-Binding Proteins genetics, Rhabdomyosarcoma, Embryonal genetics
- Abstract
Rhabdomyosarcoma (RMS) is the most common pediatric soft tissue sarcoma and rarely occurs in adults. There are six main subtypes, each histologically, clinically, and cytogenetically distinct. Embryonal RMS is characterized by chromosomal gains, usually not associated with any consistent structural anomaly. We describe here a case of embryonal RMS in a 19-year-old female patient. The conventional cytogenetic analysis showed a t(4;22)(q35;q12) translocation as the sole cytogenetic change. Complementary fluorescence in situ hybridization analysis showed that the translocation breakpoints were located in the EWSR1 gene at 22q12 and the region of the DUX4 and FSHMD1A at 4q35. This constitutes a novel example of the high frequency of EWSR1 rearrangements in various types of sarcomas as well as of its ability to fuse with a large variety of partner genes. Because DUX4 is involved in myogenic differentiation and cell-cycle control, the striated muscle differentiation observed in the present case might be a direct consequence of the alteration of the DUX4 region generated by the t(4;22). The involvement of the DUX4 region might represent the genetic hallmark of a novel subclass of small round cell tumors.
- Published
- 2009
- Full Text
- View/download PDF
33. [Apocrine lesions in breast pathology].
- Author
-
Suciu V, Menet E, Guinebretière JM, Trassard M, and Vielh P
- Subjects
- Adult, Biopsy, Breast Neoplasms pathology, Female, Fibrocystic Breast Disease pathology, Humans, Metaplasia, Apocrine Glands pathology, Breast pathology
- Published
- 2009
- Full Text
- View/download PDF
34. Superficial soft tissue sarcomas (S-STS): a study of 367 patients from the French Sarcoma Group (FSG) database.
- Author
-
Salas S, Stoeckle E, Collin F, Bui B, Terrier P, Guillou L, Trassard M, Ranchere-Vince D, Gregoire F, and Coindre JM
- Subjects
- Adolescent, Adult, Aged, Analysis of Variance, Female, France epidemiology, Humans, Immunohistochemistry, Male, Middle Aged, Neoplasm Recurrence, Local mortality, Neoplasm Staging, Prognosis, Sarcoma mortality, Sarcoma secondary, Sarcoma therapy, Soft Tissue Neoplasms therapy, Young Adult, Neoplasm Recurrence, Local pathology, Sarcoma pathology, Soft Tissue Neoplasms pathology
- Abstract
Aim: The specific natural history of superficial soft tissue sarcomas (S-STS) has been rarely considered. We describe the clinical characteristics of a large series of S-STS (N=367) from the French Sarcoma Group (GSF-GETO) database and analyse the prognostic factors affecting outcome., Methods: We performed univariate and multivariate analyses for overall survival (OS), metastasis-free survival (MFS) and local recurrence-free survival (LRFS)., Results: The median age was 59 years. Fifty-eight percent patients were female. Tumour locations were as follows: extremities, 55%; trunk wall, 35.4%; head and neck, 8% and unknown, 1.6%. Median tumour size was 3.0 cm. The most frequent tumour types were unclassified sarcoma (24.3%) and leiomyosarcoma (22.3%). Thirty-three percent of cases were grade 3. Median follow-up was 6.18 years. The 5-year OS, MFS and LRFS rates were 80.9%, 80.7% and 74.7%, respectively. Multivariate analysis retained histological type and wide resection for predicting LRFS and histological type and grade as prognostic factors of MFS. The factors influencing OS were age, histological type, grade and wide resection. STS with early invasion into but not through the underlying fascia had a significantly poorer MFS than with strict S-STS., Conclusion: S-STS represent a separate category characterised by a better outcome. Adequate surgery, i.e. wide resection, is essential in the management of S-STS.
- Published
- 2009
- Full Text
- View/download PDF
35. Prognostic factors in early-stage leiomyosarcoma of the uterus.
- Author
-
Pelmus M, Penault-Llorca F, Guillou L, Collin F, Bertrand G, Trassard M, Leroux A, Floquet A, Stoeckle E, Thomas L, and MacGrogan G
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Humans, Middle Aged, Neoplasm Invasiveness, Neoplasm Staging, Prognosis, Leiomyosarcoma pathology, Uterine Neoplasms pathology
- Abstract
Uterine leiomyosarcomas (LMSs) are rare cancers representing less than 1% of all uterine malignancies. Clinical International Federation of Gynecology and Obstetrics (FIGO) stage is the most important prognostic factor. Other significant prognostic factors, especially for early stages, are difficult to establish because most of the published studies have included localized and extra-pelvian sarcomas. The aim of our study was to search for significant prognostic factors in clinical stage I and II uterine LMS. The pathologic features of 108 uterine LMS including 72 stage I and II lesions were reviewed using standardized criteria. The prognostic significance of different pathologic features was assessed. The median follow-up in the whole group was 64 months (range, 6-223 months). The 5-year overall survival (OS) and metastasis-free interval and local relapse-free interval rates in the whole group and early-stage group (FIGO stages I and II) were 40% and 57%, 42% and 50%, 56% and 62%, respectively. Clinical FIGO stage was the most important prognostic factor for OS in the whole group (P = 4 x 10). In the stage I and II group, macroscopic circumscription was the most significant factor predicting OS (P = 0.001). In the same group, mitotic score and vascular invasion were associated with metastasis-free interval (P = 0.03 and P = 0.04, respectively). Uterine LMSs diagnosed using standardized criteria have a poor prognosis, and clinical FIGO stage is an ominous prognostic factor. In early-stage LMS, pathologic features such as mitotic score, vascular invasion, and tumor circumscription significantly impact patient outcome.
- Published
- 2009
- Full Text
- View/download PDF
36. Vascular proliferations of the skin after radiation therapy for breast cancer: clinicopathologic analysis of a series in favor of a benign process: a study from the French Sarcoma Group.
- Author
-
Gengler C, Coindre JM, Leroux A, Trassard M, Ranchère-Vince D, Valo I, Michels JJ, and Guillou L
- Subjects
- Adult, Aged, Female, Humans, Immunohistochemistry, Lymphangioma etiology, Middle Aged, Neovascularization, Pathologic etiology, Skin pathology, Breast Neoplasms radiotherapy, Lymphangioma pathology, Neoplasms, Radiation-Induced pathology, Radiotherapy adverse effects, Skin blood supply, Skin radiation effects, Skin Neoplasms etiology, Skin Neoplasms pathology
- Abstract
Background: Cutaneous vascular proliferations that occur in the field of prior radiotherapy include angiosarcoma and small, cutaneous lesions with a pseudosarcomatous pattern that previously were reported as atypical vascular lesions or benign lymphangiomatous papules., Methods: The objective of this study was to investigate the clinicopathologic features and outcomes of 56 radiation-induced vascular proliferations that occurred in 36 patients who received previous treatment for breast carcinoma. Data from all patients were retrieved from the files of the French Sarcoma Group. Immunostaining with D2.40 antibody was performed in 24 lesions., Results: All patients (median age, 52 years) had received external radiotherapy. Small papules developed within the field of prior radiotherapy (median latency interval, 66 months). Microscopically, the lesions were relatively well circumscribed, and they were located mostly in the superficial/middermis. They were composed of dilated or irregular-jagged vascular channels that were lined by a single layer of bland endothelial cells, and they demonstrated either a predominately lymphangioendothelioma-like or lymphangioma/lymphangioma circumscriptum-like growth pattern. Micropapillary tufts were common findings. Ten lesions showed additional cytologic and/or architectural atypia. Twenty of 24 lesions showed D2.40 positivity. Follow-up information was available for 31 patients (median follow-up, 48 months): Five women developed new cutaneous lesions, and 1 woman had spontaneous regression of her lesions. None of the patients developed cutaneous angiosarcoma. Five patients were lost to follow-up., Conclusions: Although vascular proliferations in irradiated skin may mimic angiosarcoma morphologically, the large majority of these lesions showed a benign clinical outcome. Despite relatively limited follow-up, the current results indicate the benign nature of these vascular proliferations.
- Published
- 2007
- Full Text
- View/download PDF
37. Diagnosis of clear cell sarcoma by real-time reverse transcriptase-polymerase chain reaction analysis of paraffin embedded tissues: clinicopathologic and molecular analysis of 44 patients from the French sarcoma group.
- Author
-
Coindre JM, Hostein I, Terrier P, Bouvier-Labit C, Collin F, Michels JJ, Trassard M, Marques B, Ranchere D, and Guillou L
- Subjects
- Adolescent, Adult, Child, Computer Systems, Female, France, Humans, Immunohistochemistry, Male, Melanoma diagnosis, Oncogene Proteins, Fusion analysis, Paraffin Embedding, Prognosis, Sarcoma, Clear Cell genetics, Survival Analysis, Transcription Factors analysis, Oncogene Proteins, Fusion genetics, Reverse Transcriptase Polymerase Chain Reaction methods, Sarcoma, Clear Cell diagnosis, Transcription Factors genetics
- Abstract
Background: Clear cell sarcoma (CCS) is a rare tumor with a very poor prognosis that occurs predominantly in the distal extremities of young adults. Most patients bear the t(12;22) reciprocal translocation, which involves the EWS and ATF1 genes. The diagnosis of CCS usually is easy but may be challenging in unusual sites, and the detection of EWS-ATF1 fusion transcripts is helpful to rule out a metastatic melanoma., Methods: Forty-four patients with CCS and 14 conventional melanomas were examined for the presence of EWS-ATF1 transcripts by using real-time polymerase chain reaction (PCR) analysis on paraffin embedded tissues, including frozen samples for 9 CCS samples and 9 melanoma samples. Prior to molecular analysis, the diagnosis of CCS was considered certain in 35 patients and as probable in 9 patients on the basis of location, histologic features, and immunohistochemical profile. Treatment modalities and follow-up were available for 41 patients with CCS., Results: EWS-ATF1 fusion transcripts were detected in 38 paraffin embedded CCS tissues (86% of all samples; 93% of interpretable samples), 3 samples (7%) were negative, and 3 samples (7%) were considered uninterpretable. Fusion transcripts were detected in 7 of 9 samples for which the diagnosis of CCS was considered probable. EWS-ATF1 transcripts were not detected in the 14 samples of melanoma. Results from frozen tissues were concordant with those from all corresponding paraffin embedded samples. Twenty-eight of 41 patients (68%) experienced lymph node and/or distant metastasis, and the 5 year-survival rate was 44%. Mitotic index and histologic grade were predictive of survival and distant metastasis., Conclusions: The results of this study showed that the molecular detection of EWS-ATF1 fusion transcript by real-time PCR on paraffin embedded tissues is a sensitive and specific method for the diagnosis of CCS. It is an efficient tool for the diagnosis of unusual tumors, especially with regard to its distinction from melanoma. The current results also confirmed the poor prognosis for patients with this tumor type. Mitotic index and grade were predictive factors for survival and distant metastasis.
- Published
- 2006
- Full Text
- View/download PDF
38. Molecular detection of early-stage laryngopharyngeal squamous cell carcinomas.
- Author
-
Temam S, Bénard J, Dugas C, Trassard M, Gormally E, Soria JC, Faivre S, Luboinski B, Marandas P, Hainaut P, Lenoir G, Mao L, and Janot F
- Subjects
- Carcinoma, Squamous Cell genetics, Cell Line, Tumor, CpG Islands genetics, Cyclin-Dependent Kinase Inhibitor p16 genetics, DNA Methylation, Humans, Hypopharyngeal Neoplasms genetics, Laryngeal Neoplasms genetics, Microsatellite Repeats genetics, Neoplasm Staging methods, Pharyngeal Neoplasms genetics, Promoter Regions, Genetic genetics, Prospective Studies, Carcinoma, Squamous Cell pathology, Hypopharyngeal Neoplasms pathology, Laryngeal Neoplasms pathology, Pharyngeal Neoplasms pathology
- Abstract
Purpose: We sought to determine whether early-stage laryngopharyngeal squamous cell carcinomas (SCC) can be detected through molecular analysis of exfoliated cells collected with the use of a pharyngoesophageal brush (PEB)., Experimental Design: Thirty-three patients with a single, untreated, early-stage (T1 or T2) SCC of the supraglottic larynx or pharynx underwent collection of cells with a PEB, followed by endoscopic biopsy of the tumor. PEB specimens were also collected from five healthy subjects. PEB samples and tumor tissue were examined for hypermethylation of p16INK4a (CDKN2) gene promoter CpG islands (assayed by methylation-specific PCR) and UT5085 tetranucleotide microsatellite instability (assayed by GeneScan analysis). PEB samples were also subjected to cytologic analysis., Results: Eight of 33 (24%) tumors exhibited a bandshift at UT5085, and 14 of 33 (42%) exhibited hypermethylation at the p16 promoter. Overall, 17 of 33 (52%) patients had at least one of the two markers in their tumor. Cytologic analysis of PEB samples revealed tumor in 4 of 33 (12%) patients; cytologic findings were normal in all five control subjects. Molecular analysis of PEB samples revealed tumor DNA in 13 of 17 (76%) patients with at least one of the two molecular markers in their tumor. Eight of 14 (57%) patients with p16 hypermethylation in their tumor and 8 of 8 (100%) patients with UT5085 microsatellite instability in their tumor had similar findings in the PEB samples. None of the PEB samples from the control subjects or patients with neither molecular marker in their tumor displayed abnormality., Conclusion: Molecular analysis of PEB samples holds promise for the early detection of early-stage laryngopharyngeal SCCs. New molecular markers need to be identified to increase the sensitivity of molecular screening.
- Published
- 2005
- Full Text
- View/download PDF
39. Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis.
- Author
-
Guillou L, Benhattar J, Bonichon F, Gallagher G, Terrier P, Stauffer E, Somerhausen Nde S, Michels JJ, Jundt G, Vince DR, Taylor S, Genevay M, Collin F, Trassard M, and Coindre JM
- Subjects
- Adolescent, Adult, Age Factors, Biomarkers, Tumor analysis, Child, Female, Humans, Male, Middle Aged, Multivariate Analysis, Neoplasm Metastasis, Prognosis, Proportional Hazards Models, Retrospective Studies, Sarcoma, Synovial pathology, Survival Rate, Oncogene Proteins, Fusion genetics, Sarcoma, Synovial diagnosis
- Abstract
Purpose: To assess the prognostic value of SYT-SSX fusion type, in comparison with other factors, in a population of 165 patients with synovial sarcoma (SS)., Patients and Methods: Data on 165 patients with SS (141 with localized disease at diagnosis) were studied retrospectively. The following parameters were examined for their potential prognostic value: age at diagnosis, sex, tumor site (extremities v proximal/truncal), size, histology, mitotic count, necrosis, histologic grade (Federation Nationale des Centres de Lutte Contre le Cancer system), stage (1997 tumor-node-metastasis system classification), surgical margin status (assessed histologically), and fusion type (SYT-SSX1 v SYT-SSX2). Median follow-up time was 37 months (range, 2 to 302 months)., Results: Among those patients with localized disease at diagnosis, median and 5-year disease-specific survivals (DSS) for the SYT-SSX1 and SYT-SSX2 subgroups were 126 months and 67.4% versus 82 months and 63.2%, respectively (P = .12). Median and 5-year metastasis-free survivals (MFS) were 84 months and 54.2% for SYT-SSX1 versus 50 months and 47.6% for SYT-SSX2 (P = .76). Univariate analyses showed that high histologic grade (grade 3), high mitotic count (>/= 10 mitoses/10 high-power fields), stage III disease, size greater than 7 cm, tumor necrosis, and presence of areas of poorly differentiated morphology were significant adverse prognostic factors for DSS and MFS, whereas SYT-SSX fusion type, tumor histology (biphasic v monophasic), and patient sex were not. Age greater than 35 years adversely affected DSS but not MFS. In multivariate analyses, histologic grade was the most significant prognostic factor for both DSS and MFS., Conclusion: For patients with localized SS, histologic grade but not SYT-SSX fusion type is a strong predictor of survival.
- Published
- 2004
- Full Text
- View/download PDF
40. [HER2 gene amplification assay: is CISH an alternative to FISH?].
- Author
-
Denoux Y, Arnould L, Fiche M, Lannes B, Couturier J, Vincent-Salomon A, Penault-Llorca F, Antoine M, Balaton A, Baranzelli MC, Becette V, Bellocq JP, Bibeau F, Ettore F, Fridman V, Gnassia JP, Jacquemier J, MacGrogan G, Mathieu MC, Migeon C, Rigaud C, Roger P, Sigal-Zafrani B, Simony-Lafontaine J, Trassard M, Treilleux I, Verriele V, and Voigt JJ
- Subjects
- Breast Neoplasms chemistry, Breast Neoplasms genetics, Carcinoma, Ductal, Breast chemistry, Carcinoma, Ductal, Breast genetics, Chromosomes, Human, Pair 17 genetics, DNA Probes, Digoxigenin analysis, Female, Humans, In Situ Hybridization, Fluorescence, Proto-Oncogene Mas, Specimen Handling, Chromogenic Compounds analysis, Genes, erbB-2, In Situ Hybridization methods, Nucleic Acid Amplification Techniques
- Abstract
The HER2 proto-oncogene encodes a transmembrane protein, which is considered to function as a growth factor receptor. Overexpression of this protein found by immunohistochemistry in about 20% of infiltrating breast carcinomas, has a predictive value of response to treatment by trastuzumab, an anti-HER2 humanized monoclonal antibody. Search for HER2 gene amplification is necessary to adapt the immunohistochemical technique quality and also in the cases of delicate analysis or weak overexpression. It is usually carried out by Fluorescence In Situ Hybridization (FISH). A more recent hybridization technique, named CISH because of its chromogenic revelation is an alternative method, which gives highly correlated results with FISH. We present details of this technique, which may be more familiar for the pathologists than FISH, because reading analysis is similar to that of immunohistochemical staining.
- Published
- 2003
41. Pleomorphic liposarcoma: clinicopathologic, immunohistochemical, and follow-up analysis of 63 cases: a study from the French Federation of Cancer Centers Sarcoma Group.
- Author
-
Gebhard S, Coindre JM, Michels JJ, Terrier P, Bertrand G, Trassard M, Taylor S, Château MC, Marquès B, Picot V, and Guillou L
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Biomarkers, Tumor analysis, Disease-Free Survival, Female, Humans, Immunohistochemistry, Liposarcoma chemistry, Liposarcoma mortality, Liposarcoma surgery, Male, Middle Aged, Neoplasm Proteins analysis, Soft Tissue Neoplasms chemistry, Soft Tissue Neoplasms mortality, Soft Tissue Neoplasms surgery, Survival Rate, Treatment Outcome, Liposarcoma pathology, Soft Tissue Neoplasms pathology
- Abstract
The clinicopathologic and immunohistochemical features of 63 pleomorphic liposarcomas are presented. There were 35 men and 28 women (median age 63 years; range 18-93 years). Tumor size ranged from 2 to 23 cm (median 10 cm). Tumor locations included lower extremity (36.5%), especially the thigh (28.5%), limb girdles (17.5%), upper extremity (16%), thoracoabdominal wall (9.5%), and internal trunk (20.5%). A total of 75% were deep seated and/or extracompartmental. Histologically, lesions show a varying combination of lipogenic and nonlipogenic areas characterized by malignant fibrous histiocytoma-like, round cell liposarcoma-like, and/or epithelioid/carcinoma-like features. A pericytic pattern was focally present in 15 (24%) tumors. Eighteen (29%) lesions were grade 2, and 45 (71%) were grade 3 sarcomas. Tumor necrosis was observed in 51 (81%) cases, vascular invasion in three, and mitotic counts ranged from 3 to 124 per 10 high power fields (median 25). Lipogenic areas were S-100 protein immunoreactive, at least focally, in 20 of 42 (48%) cases. Nonlipogenic areas showed focal reactivity for smooth muscle actin (24 of 49; 49%), desmin (9 of 48; 19%), CD34 (18 of 45; 40%), S-100 protein (5 of 49, 10%), CD68 (6 of 46, 13%), and epithelial membrane antigen (13 of 49, 26.5%). Epithelioid areas showed epithelial membrane antigen (4 of 11; 36%) but not cytokeratin (0 of 11) reactivity. Treatment procedures in 51 patients consisted of simple tumorectomy (16) and wide excision (33). Five and 31 patients received neoadjuvant and adjuvant chemotherapy and/or radiation therapy, respectively. Follow-up (48 patients, range 7-276 months; median 38 months) showed a 45% local recurrence rate and a 42.5% metastasis rate, metastases occurring mostly in lungs and pleura. Seventeen patients (35%) died of disease, of whom none was metastatic at diagnosis. Five-year overall, metastasis-free, and local recurrence-free survivals were 57%, 50%, and 48%, respectively. Patient age > or =60 years, truncal tumor location, deep situation, tumor size >5 cm, vascular invasion, and incomplete tumor excision were significant adverse prognostic factors. Tumor grade and histology did not affect patient outcome. In conclusion, pleomorphic liposarcoma is a rare, often deep-seated and limb-based aggressive and metastasizing neoplasm of late adulthood. It shows a wide range of morphologic appearances, but tumor grade and histology have no effect on patient outcome.
- Published
- 2002
- Full Text
- View/download PDF
42. Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value.
- Author
-
Spyratos F, Ferrero-Poüs M, Trassard M, Hacène K, Phillips E, Tubiana-Hulin M, and Le Doussal V
- Subjects
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antigens, Nuclear, Biopsy, Breast Neoplasms metabolism, Carcinoma, Ductal, Breast metabolism, Carcinoma, Lobular metabolism, Cell Division, DNA, Neoplasm metabolism, Female, Flow Cytometry, Humans, Immunoenzyme Techniques, Ki-67 Antigen, Middle Aged, Mitotic Index, Neoplasm Invasiveness, Neoplasm Staging, Predictive Value of Tests, Receptors, Estrogen metabolism, Receptors, Progesterone metabolism, Thymidine Kinase metabolism, Biomarkers, Tumor metabolism, Breast Neoplasms pathology, Carcinoma, Ductal, Breast pathology, Carcinoma, Lobular pathology, Nuclear Proteins metabolism
- Abstract
Background: Cell proliferation is a major determinant of the biologic behavior of breast carcinoma. MIB-1 monoclonal antibody is a promising tool for determining cell proliferation on routine histologic material. The objectives of this study were to compare MIB-1 evaluation to other methods of measuring cell proliferation, with a view to refining the cutoff used to classify tumors with low and high proliferation rates in therapeutic trials., Methods: One hundred eighty-five invasive breast carcinomas were evaluated for cell proliferation by determining monoclonal antibody MIB-1 staining, histologic parameters (Scarff-Bloom-Richardson grade and mitotic index) on paraffin sections, S-phase fraction (SPF) by flow cytometry, and thymidine-kinase (TK) content of frozen samples., Results: There was a high correlation (P = 0.0001) between the percentage of MIB-1 positive tumor cells and SPF, TK, histologic grade, and the mitotic index. Multivariate analyses including MIB-1 at 5 different cutoffs (10%, 15%, 17% [median], 20%, 25%) and the other proliferative markers showed that the optimal MIB-1 cutoff was 25% and that the mitotic index was the proliferative variable that best discriminated between low and high MIB-1 samples. A MIB-1 cutoff of 25% adequately identified highly proliferative tumors. Conversely, with a MIB-1 cutoff of 10%, few tumors with low proliferation were misclassified., Conclusions: The choice of MIB-1 cutoff depends on the following clinical objective: if MIB-1 is used to exclude patients with slowly proliferating tumors from chemotherapeutic protocols, a cutoff of 10% will help to avoid overtreatment. In contrast, if MIB-1 is used to identify patients sensitive to chemotherapy protocols, it is preferable to set the cutoff at 25%. The MIB-1 index should be combined with some other routinely used proliferative markers, such as the mitotic index., (Copyright 2002 American Cancer Society.)
- Published
- 2002
- Full Text
- View/download PDF
43. Comparison of enzyme immunoassay and immunohistochemical measurements of estrogen and progesterone receptors in breast cancer patients.
- Author
-
Ferrero-Poüs M, Trassard M, Le Doussal V, Hacène K, Tubiana-Hulin M, and Spyratos F
- Subjects
- Biopsy, Breast Neoplasms pathology, Female, Humans, Middle Aged, Neoplasm Recurrence, Local, Breast Neoplasms metabolism, Immunoenzyme Techniques, Immunohistochemistry, Receptors, Estrogen metabolism, Receptors, Progesterone metabolism
- Abstract
Before replacing enzyme immunoassay of estrogen and progesterone receptors by immunohistochemistry, results of both methods were compared on 437 samples obtained from breast cancer patients (342 primary breast carcinomas, 16 local recurrences, 49 biopsies, and 30 tumor specimens obtained after neoadjuvant treatment). Immunohistochemistry (IHC) results were first assessed semiquantitatively on the basis of the estimated proportion of positive tumor cells, and then quantitatively using the "quick score." Semiquantitative IHC hormone receptors results (positive > or = 10%) correlated well with enzyme immunoassay status (positive >15 fmol/mg protein) in 358 surgical samples (342 primary tumors and 16 recurrences), with overall concordance rates of 89.9% and 82.1%, respectively. Among the 100 discordant cases, a large intraductal carcinoma component was observed in 7 of 36 cases for estrogen receptor (ER) and 15 of 64 for progesterone receptor (PR). Thirty-five discordant cases also were observed near the cut-off values. Hormone receptor levels by enzyme immunoassay correlated strongly with the quantitative IHC "quick score." Whatever the method, hormone receptor status was associated with histologic grade (SBR) and tumor size, whereas age correlated strongly with ER positivity. Similar results were obtained for biopsy specimens and posttreatment samples. This comparison improved the reliability of the IHC technique, which is currently routinely used for ER and PR determination in the authors' institution.
- Published
- 2001
- Full Text
- View/download PDF
44. Prognostic factors in localized primary synovial sarcoma: a multicenter study of 128 adult patients.
- Author
-
Trassard M, Le Doussal V, Hacène K, Terrier P, Ranchère D, Guillou L, Fiche M, Collin F, Vilain MO, Bertrand G, Jacquemier J, Sastre-Garau X, Bui NB, Bonichon F, and Coindre JM
- Subjects
- Adult, Female, Humans, Immunohistochemistry, Male, Multivariate Analysis, Neoplasm Staging, Prognosis, Proportional Hazards Models, Retrospective Studies, Survival Analysis, Sarcoma, Synovial mortality, Sarcoma, Synovial pathology, Sarcoma, Synovial therapy
- Abstract
Purpose: To identify most significant and therapeutically relevant prognostic factors in adults with localized primary synovial sarcomas (SS) and to confirm the usefulness of the French Federation of Cancer Centers (FNCLCC) grading system, the prognostic impact of which has been already proven in soft tissue sarcomas., Patients and Methods: Data on 128 patients with nonmetastatic SS collected from a cooperative database by the FNCLCC Sarcoma Group between 1980 and 1994 were studied retrospectively. Immunohistochemistry was performed at diagnosis in 77 cases (61%). The tumors were classified as biphasic (n = 45), monophasic fibrous (n = 72), and poorly differentiated (n = 10) subtypes. Histologic grade was determined according to the FNCLCC method, and vascular invasion was assessed in every case., Results: The 5-year disease-specific survival (DSS) rate for this series of patients with localized SS was 62.9% (+/- 9.6% [SD]) with a median follow-up time of 37 months (range, 8 to 141 months). In multivariate analysis, the adverse risk factors associated with decreased DSS were International Union Against Cancer/American Joint Committee on Cancer stage III/IVA disease, male sex, and truncal tumor locations. For metastasis-free survival (MFS), disease stage III/IVA, tumor necrosis, and monophasic subtypes were the major factors associated with a less favorable prognosis. Separately, when not using disease stage, tumor necrosis, and mitotic activity, histologic grade became the most significant prognostic factor for both DSS and MFS. In addition, larger tumors and older patients become associated with a significantly worse prognosis. Independent adverse risk factors for local recurrence-free survival included histologic grade 3 and truncal tumor location., Conclusion: These data confirm that not all SS present the same severe outcome. High-risk patients identified on the basis of these parameters may qualify for an aggressive treatment approach.
- Published
- 2001
- Full Text
- View/download PDF
45. Detection of the synovial sarcoma translocation t(X;18) (SYT;SSX) in paraffin-embedded tissues using reverse transcriptase-polymerase chain reaction: a reliable and powerful diagnostic tool for pathologists. A molecular analysis of 221 mesenchymal tumors fixed in different fixatives.
- Author
-
Guillou L, Coindre J, Gallagher G, Terrier P, Gebhard S, de Saint Aubain Somerhausen N, Michels J, Jundt G, Vince DR, Collin F, Trassard M, Le Doussal V, and Benhattar J
- Subjects
- Adult, Biomarkers, Tumor, DNA, Complementary genetics, Female, Fixatives, Humans, Male, Middle Aged, Neoplasms, Connective and Soft Tissue genetics, Neoplasms, Connective and Soft Tissue pathology, Paraffin Embedding, Pathology, Clinical, RNA, Neoplasm genetics, Reproducibility of Results, Reverse Transcriptase Polymerase Chain Reaction, Sarcoma, Synovial genetics, Chromosomes, Human, Pair 18 genetics, Oncogene Proteins, Fusion genetics, Sarcoma, Synovial pathology, Translocation, Genetic, X Chromosome genetics
- Abstract
Synovial sarcoma (SS) is a relatively rare sarcoma, which may be confused with several other mesenchymal and nonmesenchymal lesions. It bears the t(X;18) (SYT;SSX) translocation, which seems to be specific for this tumor type and can be detected in paraffin-embedded tissue, using reverse transcriptase-polymerase chain reaction (RT-PCR). However, the specificity and sensitivity of this detection method have rarely been examined in a large series. Using RT-PCR, we examined 250 mesenchymal and nonmesenchymal, benign and malignant, paraffin-embedded lesions for the SS t(X;18) (SYT-SSX) translocation. PCR products were obtained from 221 tumors (88.5%). There were 135 non-SS tumors, 22 biphasic, and 64 monophasic spindle/round cell SS, of which 10 were cytogenetically confirmed as t(X;18)-positive. SYT-SSX gene fusion transcripts were detected in the SS tumor category only (100% specificity), including 100% of the biphasic SS and 86% of monophasic spindle/round cell SS. Nine tumors originally diagnosed as SS were t(X;18) (SYT-SSX)-negative. Following reassessment, only 3 of these tumors showed clinicopathologic, immunohistochemical, and/or ultrastructural features consistent with that diagnosis, thus raising the overall detection sensitivity to 96%. With regard to the potential adverse effect of the fixatives used, PCR products were obtained in 100%, 91.5%, 90.5%, and 0% of tumors fixed with AFA, buffered formalin, Holland Bouin, and conventional Bouin's fluid, respectively. This study shows that the detection of the SS t(X;18) (SYT-SSX) in paraffin-embedded tissue is feasible with a 100% specificity and an overall 96% sensitivity, provided non-Bouin's fluid fixation is used.
- Published
- 2001
- Full Text
- View/download PDF
46. Somatic genetic alterations (LOH) in benign, borderline and invasive ovarian tumours: intratumoral molecular heterogeneity.
- Author
-
Zborovskaya I, Gasparian A, Karseladze A, Elcheva I, Trofimova E, Driouch K, Trassard M, Tatosyan A, and Lidereau R
- Subjects
- Chromosomes, Human, Pair 1, Chromosomes, Human, Pair 11, Chromosomes, Human, Pair 17, Chromosomes, Human, Pair 18, Chromosomes, Human, Pair 7, Female, Genetic Markers, Humans, Neoplasm Invasiveness, Neoplasm Metastasis, Neoplasm Staging, Ovarian Neoplasms pathology, Chromosome Mapping, Loss of Heterozygosity, Ovarian Neoplasms genetics
- Abstract
Loss of heterozygosity (LOH) affects a number of chromosome regions in ovarian cancer, pointing to the possible involvement of tumour-suppressor genes in ovarian tumorigenesis. We performed comparative analysis of allelic loss at 6 frequently affected chromosome regions in a panel of 53 benign, borderline and malignant ovarian tumours. Precursor lesions could provide evidence that an accumulation of genetic events is required for normal ovarian epithelium to generate malignant tumours. LOH on chromosome 1p was relatively common in benign, borderline and malignant tumours, while at 11p and 7q it was observed not only in invasive but also in borderline tumours. Moreover, 17q and 18q were affected mainly in advanced malignant tumours and revealed a high frequency of clonal intratumoral heterogeneity. We encountered different spectra of genetic alterations in primary tumours and their metastasis, which may be the results of intratumoral heterogeneity leading to dissemination in only some sub-clones., (Copyright 1999 Wiley-Liss, Inc.)
- Published
- 1999
- Full Text
- View/download PDF
47. [Intraoperative cytology of breast lesions].
- Author
-
Briffod M, Cabaret V, Trassard M, and Labbé S
- Subjects
- Breast Diseases surgery, Breast Neoplasms surgery, Female, Frozen Sections, Humans, Intraoperative Period, Reproducibility of Results, Breast pathology, Breast Diseases pathology, Breast Neoplasms pathology
- Abstract
Evaluation of intraoperative cytology and frozen sections for breast lesions is essential to single-stage and cost effective management. The aim of this study is to evaluate the diagnostic accuracy and the potential role of intraoperative cytology. The results of the study undertaken at the René Huguenin Center and the data of the literature suggest that intraoperative cytology may be helpful in some cases, especially as an adjunct to frozen sections. If frozen sections could be avoided any time clear features of benignity or malignancy are offered by both clinical data and macroscopic and cytologic examination, this approach does have limitations. Intraoperative cytology should not be used as an alternative to frozen sections except, in a few cases, when technical conditions required for them are not available or suitable. It can also constitute a good way for continuous education of our cytotechnologists.
- Published
- 1999
48. Analysis of alterations adjacent to invasive vulvar carcinoma and their relationship with the associated carcinoma: a study of 67 cases.
- Author
-
Vilmer C, Cavelier-Balloy B, Nogues C, Trassard M, and Le Doussal V
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Humans, Lichen Sclerosus et Atrophicus pathology, Middle Aged, Neoplasm Invasiveness, Retrospective Studies, Carcinoma, Squamous Cell pathology, Vulvar Neoplasms pathology
- Abstract
A retrospective analysis of histological lesions adjacent to 67 invasive vulvar squamous cell carcinomas (SCC) was undertaken to analyse their nature, as well as their relationship to SCC. Patient age, clinical presentation and histological type of carcinoma, ISSVD classification of its adjacent lesions, disease-free and overall survival were reviewed. Severe undifferentiated vulvar intra-epithelial neoplasia (VIN3) was found in 19.4% of cases and vulvar lichen sclerosus (VLS) in 76.1% of cases. All VLS, except 2 cases, were associated with squamous cell hyperplasia (SCH), and a concomitant differentiated VIN was found in 76.6% of cases. Undifferentiated VIN3 was never associated with VLS. VLS was significantly associated with a keratinizing, well-differentiated SCC (98% of cases), while undifferentiated VIN3, was linked preferentially to 2 other types of SCC: in 77% of cases, a moderately-differentiated SCC with the same histological features as the so-called basaloid carcinoma and, in 23% of cases, a well-differentiated SCC with a variable extent of koilocytic atypia, similar to the so-called warty carcinoma. Carcinoma of the fourchette was more often associated with undifferentiated VIN3. Disease-free and overall survival were significantly better for carcinoma associated with undifferentiated VIN3 (p < 0.01 and p < 0.05, respectively). These findings suggest invasive vulvar SCC occurs on 2 distinct types of vulvar lesions: differentiated VIN and/or SCH associated with VLS and undifferentiated VIN3. Furthermore, the histological type of the carcinoma seems to differ according to adjacent lesions.
- Published
- 1998
49. Angiosarcoma arising in a solitary schwannoma (neurilemoma) of the sciatic nerve.
- Author
-
Trassard M, Le Doussal V, Bui BN, and Coindre JM
- Subjects
- Aged, Biomarkers, Hemangiosarcoma chemistry, Hemangiosarcoma complications, Humans, Immunohistochemistry, Male, Microscopy, Electron, Neoplasms, Multiple Primary chemistry, Neoplasms, Nerve Tissue chemistry, Neoplasms, Nerve Tissue complications, Neoplasms, Vascular Tissue chemistry, Neoplasms, Vascular Tissue complications, Neurilemmoma chemistry, Neurilemmoma complications, Sciatic Nerve chemistry, Thigh pathology, Thigh surgery, Hemangiosarcoma pathology, Neoplasms, Multiple Primary pathology, Neoplasms, Nerve Tissue pathology, Neoplasms, Vascular Tissue pathology, Neurilemmoma pathology, Sciatic Nerve pathology
- Abstract
Angiosarcomas rarely develop within a peripheral nerve or a peripheral nerve sheath tumor. We describe an epithelioid angiosarcoma that arose in a benign schwannoma (neurilemoma) of the right thigh in a 65-year-old man who did not have von Recklinghausen's disease. Histologically, the resected tumor was a high-grade undifferentiated sarcoma that was predominantly arranged in solid sheets or nests and composed of epithelioid cells. The endothelial origin of the tumor was suggested by Factor VIII R-ag, Ulex europaeus-I, CD34, CD31, BNH9, and vimentin immunoreactivity, along with the ultrastructural evidence of occasional Weibel-Palade bodies. In this location, epithelioid angiosarcoma should be distinguished from malignant transformation of a schwannoma with epithelioid changes. This observation stresses the importance of immunohistochemical and ultrastructural analysis in the differential diagnosis of vascular tumors with features of epithelioid sarcoma.
- Published
- 1996
- Full Text
- View/download PDF
50. [A case for diagnosis: cutaneous metastasis of breast carcinoma].
- Author
-
Vilmer C and Trassard M
- Subjects
- Female, Humans, Middle Aged, Scalp, Skin Neoplasms pathology, Adenocarcinoma pathology, Alopecia etiology, Breast Neoplasms pathology, Skin Neoplasms secondary
- Published
- 1993
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.